- Price
- $34.59
- Day
- +3.81%
- Mkt Cap
- $24.99B
- 52W Range
- $10.90 – $37.00
- Volume
- 5.88M
- Beta
- 1.11
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
California State Teachers Retirement System boosted its holdings in shares of Roivant Sciences Ltd. (NASDAQ: ROIV) by 22.9% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 440,634 shares of the company's stock after acquiring an additional 82,075
Read full article
Allspring Global Investments Holdings LLC purchased a new stake in Roivant Sciences Ltd. (NASDAQ: ROIV) in the undefined quarter, according to its most recent filing with the SEC. The institutional investor purchased 142,134 shares of the company's stock, valued at approximately $3,957,000. Other hedge funds also recently added to or reduced their stakes
Read full article
Bank of Nova Scotia cut its stake in Roivant Sciences Ltd. (NASDAQ: ROIV) by 7.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,310,387 shares of the company's stock after selling 112,613 shares during the quarter. Bank of Nova Scotia
Read full article
BASEL, Switzerland and LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026, to report its financial results for the first quarter ended June 30, 2026, and provide a business update.
Read full article
DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the first quarter ended June 30, 2026 on Thursday, August 6, 2026 before the market opens.
Read full article